Form 4: BioLife Solutions CFO Sells Shares Under 10b5-1 Trading Plan

BioLife Solutions' Chief Financial Officer, Troy Wichterman, sold 147 shares of common stock at $26.19 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Troy Wichterman, the Chief Financial Officer of BioLife Solutions Inc., sold 147 shares of the company's common stock on November 12, 2024.
• The shares were sold at a price of $26.19 per share.
• This transaction was executed under a pre-existing Rule 10b5-1(c) trading plan adopted by Mr. Wichterman on August 9, 2021.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, Mr. Wichterman directly owns 123,347 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without the appearance of trading on non-public information.
• Many executives at comparable companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR) also utilize similar trading plans.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the small number of shares sold and the pre-arranged nature of the transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, Form 4, Troy Wichterman, 10b5-1 plan, stock sale, CFO, executive compensation